Skip to content

Effect of peripheral nerve block and tracheal intubation general anesthesia on PND in elderly patients undergoing total hip replacement

Effect of peripheral nerve block and tracheal intubation general anesthesia on PND in elderly patients undergoing total hip replacement

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020557
Enrollment
Unknown
Registered
2019-01-08
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative neurocognitive disorders

Interventions

1:General anesthesia with tracheal intubation
2:Peripheral nerve block

Sponsors

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Patients who are scheduled to undergo total hip arthroplasty; 2) Aged over 65 years old; 3) ASA grade I to III; 4) Voluntary signature of informed consent.

Exclusion criteria

Exclusion criteria: 1) Refusal to participate in this study; 2) Communication barriers, inability to cooperate with researchers, such as language comprehension barriers, mental illness and illiteracy, unable to communicate with doctors, etc.; 3) suffering from cerebrovascular disease, dementia and Alzheimer's disease; 4) Identify/suspect persons with a history of alcohol, analgesics or other substances abuse and addiction; 5) Unstable angina pectoris and myocardial infarction occurred within 3 months; NYHA grade (> 3) of cardiac function; 6) Preoperative visit with blood pressure (> 180/110 mm Hg) (WHO-ISH hypertension guideline grade 3 hypertension); 7) Diabetic patients with diabetic complications (diabetic ketoacidosis, hypertonic coma, various infections, macroangiopathy, diabetic nephropathy, retinopathy, diabetic cardiomyopathy, diabetic neuropathy, diabetic foot, etc.); 8) Severe abnormalities of liver and kidney function (severe abnormalities of liver function: ALT, conjugated bilirubin, AST, ALP, total bilirubin > 2 times the upper limit of normal value; severe abnormalities of kidney function: Cr clearance rate 177 umol/L); 9) Participated in other clinical trials within 3 months before being selected for the study.

Design outcomes

Primary

MeasureTime frame
CAM-ICU;

Secondary

MeasureTime frame
Hippocampal gyrus volume;Routine blood test;IL-6;CRP;Postoperative pain score;

Countries

China

Contacts

Public ContactWu Xianping

Shunde Hospital of Guangzhou University of Traditional Chinese Medicine

sdwxp@163.com+86 13509969196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026